Literature DB >> 9390114

Buprenorphine withdrawal syndrome in a newborn.

P Marquet1, J Chevrel, P Lavignasse, L Merle, G Lachâtre.   

Abstract

A pregnant woman who was addicted to heroin rapidly withdrew from illicit drugs after the onset of a 4 mg/day buprenorphine treatment. In the newborn's blood, urine, and meconium 20 hours after birth, high concentrations of buprenorphine and its metabolite norbuprenorphine were detected, with a higher buprenorphine/norbuprenorphine ratio than in adults, possibly as a consequence of immature hepatic function; no illicit drugs were found. The child had a weak withdrawal syndrome on the second day of life and recovered rapidly. The measured buprenorphine daily dose ingested by the newborn through mother's milk was very low (3.28 micrograms) and probably had little pharmacologic effect because no withdrawal signs could be noted when maternal feeding was later abruptly interrupted. Further investigations are required to determine whether buprenorphine can be considered to be a good alternative to methadone in the treatment of pregnant heroin addicts to prevent marked withdrawal syndromes in newborns.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390114     DOI: 10.1016/S0009-9236(97)90053-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.

Authors:  Sarah Reece-Stremtan; Kathleen A Marinelli
Journal:  Breastfeed Med       Date:  2015-04       Impact factor: 1.817

Review 2.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

Review 4.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

5.  ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman.

Authors:  Lauren M Jansson
Journal:  Breastfeed Med       Date:  2009-12       Impact factor: 1.817

6.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Authors:  Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Pediatrics       Date:  2008-08-11       Impact factor: 7.124

7.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

Review 8.  Drug transfer and metabolism by the human placenta.

Authors:  Michael R Syme; James W Paxton; Jeffrey A Keelan
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.